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INTRODUCTION
Atrial fibrillation (AF) is the most common form of sustained 
cardiac arrhythmia.1 The prevalence of AF in the general pop-
ulation increase with age, and is estimated to affect over 4% of 
the population above the age of 60 years.2-4 Foremost, electri-
cal and chemical cardioversions have been successfully utilized 
for rhythm control in AF.5 However, it has been reported that 
cardioversion in patients with AF is associated with complica-
tions including thromboembolic events (5–7%) and bradyar-
rhythmias (0.8–1.5%).6-8 Adequate anticoagulation may, in 
part, attenuate the risk associated with thromboembolic events; 
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Purpose: Electric cardioversion has been successfully used in terminating symptomatic atrial fibrillation (AF). Nevertheless, large-
scale study about the acute cardiovascular events following electrical cardioversion of AF is lacking. This study was performed to 
evaluate the incidence, risk factors, and clinical consequences of acute cardiovascular events following electrical cardioversion of AF.
Materials and Methods: The study enrolled 1100 AF patients (mean age 60±11 years) who received cardioversion at four tertiary 
hospitals. Hospitalizations for stroke/transient ischemic attack, major bleedings, and arrhythmic events during 30 days post elec-
tric cardioversion were assessed.
Results: The mean duration of anticoagulation before cardioversion was 95.8±51.6 days. The mean International Normalized Ra-
tio at the time of cardioversion was 2.4±0.9. The antiarrhythmic drugs at the time of cardioversion were class I (45%), amiodarone 
(40%), beta-blocker (53%), calcium-channel blocker (21%), and other medication (11%). The success rate of terminating AF via 
cardioversion was 87% (n=947). Following cardioversion, 5 strokes and 5 major bleedings occurred. The history of stroke/transient 
ischemic attack (OR 6.23, 95% CI 1.69–22.90) and heart failure (OR 6.40, 95% CI 1.77–23.14) were among predictors of thrombo-
embolic or bleeding events. Eight patients were hospitalized for bradyarrhythmia. These patients were more likely to have had a 
lower heart rate prior to the procedure (p=0.045). Consequently, 3 of these patients were implanted with a permanent pacemaker.
Conclusion: Cardioversion appears as a safe procedure with a reasonably acceptable cardiovascular event rate. However, to pre-
vent the cardiovascular events, several risk factors should be considered before cardioversion.
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in patients with adequate anticoagulation, the event rate is re-
ported to be between 0.7% and 0.8%.9-12
Current guidelines advocate for patients with AF lasting more 
than 48 hours to achieve therapeutic International Normal-
ized Ratio (INR) for 3 weeks prior to cardioversion and main-
tain anticoagulation treatment for at least 4 weeks following 
cardioversion. If patient has not been anticoagulated for the 
preceding 3 weeks, it is reasonable to perform a transesopha-
geal echocardiography (TEE) prior to cardioversion.1,13 How-
ever, given these recommendations generally stem from small 
observational studies, therefore, there is a need for additional 
verification via larger sized datasets of varying study samples. 
Furthermore, in terms of bradyarrhythmia, the paucity of data 
regarding the predictors of cardioversion complications re-
mains equivocal to date.14-16 Hence, the comprehensive safety 
analysis including thromboembolic, bleeding, and arrhyth-
mic events from electric cardioversion in recurrent and per-
sistent AF in various ethnicities requires further clarification. 
In the current study, we explored the presence of risk factors 
and their association with thromboembolic, major bleeding, 
and arrhythmic events following electrical cardioversion of AF 
lasting beyond 48 hours with appropriate anticoagulation fol-
lowing current guidelines. 
MATERIALS AND METHODS
The present study comprised a retrospective analysis of 1100 
patients from January 2005 through August 2013 at four tertia-
ry hospitals in Korea. Although the number of cardioversion 
was 1597, this study evaluated only the initial cardioversion in 
each patient. Patients with AF with the duration of 48 hours or 
more taking warfarin and underwent electric cardioversion 
were enrolled for evaluation. Patients taking new oral antico-
agulant were excluded. All case records were reviewed follow-
ing the standardized data collection protocol for the purpose 
of obtaining information: baseline characteristics including 
age, gender, diabetes, hypertension, heart failure, and history 
of stroke or myocardial infarction; medication use; manage-
ment of patients during the initial cardioversion and the 30-
day follow-up period after cardioversion. The CHADS2 score 
[Congestive heart failure, Hypertension, Age ≥75, Diabetes, 
prior ischemic Stroke, transient ischemic attack (TIA) or throm-
boembolism (doubled)], CHA2DS2-VASc score [Congestive 
heart failure or left ventricular dysfunction Hypertension, Age 
≥75 (doubled), Diabetes, prior ischemic Stroke, TIA or throm-
boembolism (doubled), Vascular disease, Age 65–74, gender 
category (female)], and HAS-BLED (Hypertension, Abnormal 
renal or liver function, Stroke, Bleeding tendency or predispo-
sition, Labile INRs, Elderly, Drugs or alcohol abuse) were cal-
culated as indices of thromboembolic or major bleeding risks. 
Before patients begin taking warfarin, INR was checked and 
warfarin was prescribed considering patient’s body weight, 
age, and laboratory test result. Then, the dose was modulated 
according to the target INR level between 2.0 and 3.0 at 1 or 2 
weeks interval. When INR level remained same for at least 1 
to 2 weeks, INR level was measured once a month.
Diagnosis of AF was based on a 12-lead electrocardiogram 
(ECG) characterized by the absence of discrete P waves and 
an irregular ventricular rate. For the majority of patients, a sin-
gle ECG was sufficient to secure diagnosis, assuming the pa-
tient is in AF at the time of the ECG. For the remaining patients, 
AF was diagnosed by employing a heart rhythm recording such 
as telemetry strip or Holter monitor. Synchronized direct-cur-
rent cardioversions were performed according to the current 
guidelines with the monitoring of ECG, pulse rate, oxygen sat-
uration, and cardiac telemetry under sedation with intrave-
nous injection of pentothal sodium. Cardioversion energy was 
set to 100 to 200 joules for biphasic devices. Cardioversion was 
defined as successful if sinus rhythm was obtained and patient 
was discharged from the cardioversion unit in sinus rhythm. If 
first cardioversion had failed, second or third cardioversion 
was performed. To reduce the risk of thromboembolism fol-
lowing cardioversion, anticoagulation was performed accord-
ing to current guidelines three to four weeks before and after 
cardioversion. Alternatively, TEE was performed to evaluate the 
presence of existing intra-cardiac thrombus within 24 hours 
before electrical cardioversion depending on the physician’s 
decision. In some patients with lower INR levels, intravenous 
unfractionated heparin was administered at the time of car-
dioversion.
The outcome in this study was hospitalization due to cardio-
vascular events after cardioversion during 30 days, which com-
prised the following: 1) thromboembolic (stroke/TIA, systemic 
embolism), 2) major bleedings, and 3) arrhythmic events. 
Stroke was defined as the sudden onset of a focal neurological 
deficit in a location consistent with the territory of a major ce-
rebral artery and categorized as ischemic, hemorrhagic, or 
unspecified. Hemorrhagic transformation of ischemic stroke 
was not considered hemorrhagic stroke. Intracranial hemor-
rhage consisted of hemorrhagic stroke and subdural or sub-
arachnoid hemorrhage. Systemic embolism was defined as an 
acute vascular occlusion of an extremity or organ document-
ed by means of imaging, surgery, or autopsy. Major bleeding 
was defined as a reduction in the hemoglobin level of at least 
20 g/L, transfusion of at least 2 unit blood, or symptomatic bl-
eeding in a critical area or organ. Patients with symptomatic 
significant bradycardia were hospitalized. Significant brady-
cardia was defined as bradycardia requiring medication or 
pacing, heart rate lower than 40 beats per minute, or asystole 
lasting longer than 5 seconds. Other arrhythmic events in-
cluding ventricular tachycardia and fibrillation also evaluated.
Continuous variables are reported as mean±standard devi-
ation, and were analyzed using independent t-test. Categorical 
variables were reported as counts and proportions, and ana-
lyzed using Pearson’s chi-square tests or Fisher’s exact test, as 
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appropriate. We performed univariate analysis and, with vari-
ables found to be statistically significant on univariate analy-
sis, multivariate logistic regression analysis was performed to 
evaluate independent predictors for cardiovascular events. 
The SPSS statistical package (SPSS Inc., Chicago, IL, USA) was 
used to perform all statistical evaluations. A p value of <0.05 was 
considered statistically significant. The study protocol was ap-
proved by the Institutional Review Boards. The authors had full 
access to and take full responsibility for the integrity of the data. 
All authors have read and agreed to the manuscript as written.
RESULTS
The clinical characteristics of patients according to the throm-
boembolic or bleeding events are presented in Table 1. The 
average duration of anticoagulation before cardioversion was 
96±52 days. Mean INR were 2.43±0.89 and 2.38±0.92 at the 
time of cardioversion and 30-day follow-up, respectively. The 
proportion of patients with INR ≥2 at the time of cardioversion 
were 89% (n=893). The antiarrhythmic drugs used at the time 
of cardioversion were flecainide (n=494, 45%), amiodarone 
(n=445, 40%), beta-blocker (n=585, 53%), calcium-channel 
blocker (n=226, 21%) and others (n=119, 11%). Cardioversion 
was successful in 947 patients (87%). In 1080 (98%) patients, 
follow-up more than 30 days were possible.
Thromboembolism and bleeding events
After cardioversion, five stroke events (0.5%) and five major 
bleeding events (0.5%) occurred during 30-days follow-up pe-
riod. Patients with thromboembolic and bleeding events were 
older (67±11 years vs. 60±11 years, p=0.042) and had previous 
stroke (50% vs. 13%, p=0.006) than those without events. Pa-
tients with high CHADS2 (≥3) and CHA2DS2-VASc score (≥6) 
were more common in the event group compared with the 
non-event group (p=0.015 and p<0.001, respectively). Also, 
HAS-BLED score of the event group was significantly higher 
than the non-event group (p<0.001). There was no significant 
difference in INR at the time of cardioversion between event 
and non-event groups (2.3±0.6 vs. 2.4±0.9, p=0.59) (Table 1).
Table 1. Baseline Characteristics of Study Population According to Hospitalization due to Thromboembolic or Bleeding Events at Follow Up 30-Days 
after Cardioversion
Variables Total (n=1100)
Thromboembolic or bleeding
p value
Yes (n=10) No (n=1090)
Age 60±11 67±11 60±11 0.042
Gender, female 284 (26) 2 (20) 282 (26) 1.0
Diabetes 267 (25) 3 (30) 264 (24) 0.713
Hypertension 686 (63) 7 (70) 679 (63) 0.752
History of stroke/TIA 147 (13) 5 (50) 142 (13) 0.006
Heart failure 163 (15) 5 (50) 158 (15) 0.009
Myocardial infarction 38 (4) 1 (10) 37 (3) 0.299
CHADS2 score 1.3±1.1 2.6±1.8 1.3±1.1 0.044
CHADS2 score ≥3 151 (14) 4 (40) 147 (14) 0.015
CHA2DS2-VASc score 1.7±1.4 3.9±2.7 1.7±1.4 0.029
CHA2DS2-VASc ≥6 14 (1) 4 (40) 10 (1) <0.001
HAS-BLED score 2.0±1.2 3.4±1.2 1.9±1.2 <0.001
HAS-BLED score ≥4 114 (10) 6 (60) 108 (10) <0.001
TEE prior to cardioversion 162 (15) 3 (30) 159 (15) 0.172
INR at cardioversion 2.4±0.9 2.3±0.6 2.4±0.9 0.586
Cardioversion success 947 (87) 8 (80) 939 (87) 0.376
Medications
Flecainide 494 (45) 5 (50) 489 (45) 0.760
Amiodarone 445 (40) 5 (50) 440 (40) 0.537
Beta-blocker 585 (53) 4 (40) 581 (53) 0.529
Calcium-channel blocker 226 (21) 1 (10) 225 (21) 0.697
Others 119 (11) 0 119 (11) 0.612
CHADS2, Congestive heart failure, Hypertension, Age ≥75, Diabetes mellitus, and prior ischemic Stroke or transient ischemic attack (doubled); CHA2DS2-VASc, 
Congestive heart failure, Hypertension, Age ≥75 (doubled), Diabetes mellitus, and prior ischemic Stroke, transient ischemic attack or thromboembolism (dou-
bled), Vascular disease, Age 65 to 74, Sex category (female); HAS-BLED, Hypertension, Abnormal renal/liver function, Stroke, Bleeding tendency or predisposi-
tion, Labile INR, Elderly (e.g. >65), Drugs (e.g., aspirin, clopidogrel or non-steroidal antiinflammatory drug), alcohol abuse; INR, International Normalised Ratio; 
TEE, transesophageal echocardiography; TIA, transient ischemic attack.
Numbers in parenthesis represent percentage.
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Details of the patients hospitalized due to thromboembolic 
or bleeding events are presented in Table 2. Patients with 
stroke had a high CHADS2 score ≥2. The level of INR was be-
low 2 in a patient who suffered a stroke within a week after 
electric cardioversion. Conversely, patients suffering a stroke 
beyond one week after cardioversion had an INR of more 
than 2. All five patients with major bleeding presented with a 
HAS-BLED score equal or above than 3. In only one patient, 
the INR level was above 3. On multivariate logistic regression 
analysis for thromboembolic or bleeding events within 30 
days after cardioversion, heart failure [odds ratio (OR) 6.40, 
95% confidence interval (CI) 1.77–23.14, p=0.005] and history 
of stroke/TIA (OR 6.23, 95% CI 1.69–22.90, p=0.006) were 
found to be independent predictors (Table 3).
Arrhythmic events
Eight (0.7%) patients were hospitalized for bradyarrhythmia. 
Baseline characteristics of patients according to the arrhyth-
mic events are summarized in Table 4. Heart rate pre- and post- 
cardioversion was lower in patients hospitalized with brady-
cardia than those without (p=0.01, p=0.045, respectively). The 
number of antiarrhythmic drugs before cardioversion was not 
significantly different between 2 groups (2.1±1.1 vs. 1.7±0.8, 
p=0.11). The types of arrhythmia were as follows: junctional 
bradycardia (n=3), sinus bradycardia (n=2), sinus pause (n=2), 
and tachybradycardia (n=1) (Table 5). Three patients received 
permanent pacemaker implantation, while the other patients 
were managed by changing or discontinuation of antiarrhyth-
mic drugs.
Table 2. Characteristics of Patients with Hospitalization due to Thromboembolic or Bleeding Events in 30 Days after Electric Cardioversions
No. Sex/age
Event 
characteristics
Days after 
cardioversion
CHADS2/
CHA2DS2-VASc
HAS-
BLED
INR at 
cardioversion
INR at 
admission
Type of 
anticoagulation/
drugs
Management
Thromboembolic events
1 M/70
Ischemic stroke, 
  left occipital 
  multiple lacuna
2 2/3 3 2.5 1.8 Warfarin, aspirin
Increase the target 
  level of INR
2 M/43 Lt. renal infarction 2 2/2 1 2.0 1.15 Warfarin
Renal artery 
  thrombectomy and 
  Increase the target 
  level of INR
3 M/68
Ischemic stroke, 
  right basal ganglia, 
  hemorrhagic 
  transformation 
3 4/6 4 2.1 1.7 Warfarin, aspirin
Restart of warfarin 
  and aspirin after the 
  resolution of 
  hemorrhage 
4 M/75
Ischemic stroke, 
  left basal ganglia, 
  and corona radiata
9 6/8 4 3.0 3.2 Warfarin, aspirin
Add cilostazole 
  to warfarin
5 F/77
Ischemic stroke, 
  right frontal lobe 
15 5/6 4 2.7 2.8 Warfarin
Increase the target 
  level of INR
Bleeding events
6 M/82
Vocal cord edema 
  and bleeding
1 5/7 4 2.5 2.5 Warfarin
Discontinuation 
  of warfarin
7 M/69
Gastrointestinal 
  bleeding
1 1/3 3 2.4 2.0 Warfarin
Discontinuation 
  of warfarin
8 M/54
Hematoma at 
  iliopsoas and iliacus 
  muscle
4 1/1 5 2.5 3.7 Warfarin
Discontinuation 
  of warfarin 
9 F/72
Gastrointestinal 
  bleeding
7 2/3 4 2.2 1.9 Warfarin
Discontinuation 
  of warfarin
10 M/63
Gastrointestinal 
  bleeding
30 2/2 3 2.6 2.9 Warfarin
Discontinuation 
  of warfarin
F, female; M, male; No., patient number; INR, International Normalised Ratio; CHADS2, Congestive heart failure, Hypertension, Age ≥75, Diabetes mellitus, and 
prior ischemic Stroke or transient ischemic attack (doubled); CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥75 (doubled), Diabetes mellitus, and 
prior ischemic Stroke, transient ischemic attack or thromboembolism (doubled), Vascular disease, Age 65 to 74, Sex category (female); HAS-BLED, Hypertension, 
Abnormal renal/liver function, Stroke, Bleeding tendency or predisposition, Labile INR, Elderly (e.g. >65), Drugs (e.g., aspirin, clopidogrel or non-steroidal antiin-
flammatory drug), alcohol abuse.
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In the univariate logistic model for arrhythmic events with-
in 30 days after cardioversion, heart rate pre- (OR 0.95, 95% CI 
0.89–0.99, p=0.046) and post- (OR 0.88, 95% CI 0.80–0.97, p= 
0.008) cardioversion were independent predictors of arrhyth-
mic events after cardioversion. 
DISCUSSION
Main findings
In this study, we examined the presence of risk factors and their 
association with cardiovascular events following electrical car-
dioversion of AF. The cardiovascular events rate of elective car-
dioversion for AF using current consensus recommendation 
was low. Of 1100 patients, there were 18 (1.6%) cases of cardio-
vascular events related hospitalizations. Heart failure and his-
tory of stroke/TIA were strong predictors of thromboembolic or 
bleeding events. There was a low heart rate pre- and post-car-
dioversion in those who experienced an arrhythmic event.
Thromboembolism and bleeding events 
The success rate of cardioversion was 87% in this study, which 
Table 3. Univariate and Multivariate Analysis of Predictors of Thromboembolic or Bleeding Events after Cardioversion
Variables
Univariate analysis Multivariate analysis
OR (95% CI) p value OR (95% CI) p value
Age 1.07 (1.00–1.14) 0.04 1.05 (0.98–1.12) 0.15
History of stroke/TIA 6.62 (1.89–23.15) 0.003 6.23 (1.69–22.90) 0.006
Heart failure 5.85 (1.67–20.43) 0.006 6.40 (1.77–23.14) 0.005
OR, odds ratio; CI, confidence interval; TIA, transient ischemic attack.
Table 4. Baseline Characteristics of Study Population According to Hospitalization due to Arrhythmic Events at Follow Up 30-Days after Cardioversion
Variables
Bradyarrhythmia
p value
Yes (n=8) No (n=1092)
Age 55±15 60±11 0.234
Gender, female 4 (50) 280 (26) 0.216
Diabetes 2 (25) 265 (24) 1.0
Hypertension 3 (38) 683 (63) 0.156
Heart failure 2 (25) 161 (15) 0.341
History of stroke 1 (13) 146 (14) 1.0
History of MI 0 38 (4) 1.0
Heart rate at pre-cardioversion 64±12 77±19 0.045
Heart rate at post-cardioversion 49±7 61±12 0.01
TEE prior to cardioversion 0 162 (15) 0.613
Unsuccessful cardioversion 0 138 (13) 0.275
Medications
Flecainide 6 (75) 488 (45) 0.150
Amiodarone 2 (25) 443 (41) 0.485
Beta-blocker 6 (75) 579 (53) 0.295
Calcium-channel blocker 1 (13) 225 (21) 1.0
Others 2 (25) 117 (11) 0.211
TEE, transesophageal echocardiography; MI, myocardial infarction.
Numbers in parenthesis represent percentage.
Table 5. Characteristics of Patients with Hospitalization due to Arrhythmic Events in 30 Days after Electric Cardioversions
No. Sex/age Characteristics (ECG findings) Days after cardioversion Antiarrhythmic drug Management
1 M/73 Sick sinus syndrome (Junctional bradycardia) 0 Diltiazem, amidarone Discontinuation of AAD
2 F/79 Sick sinus syndrome (Junctional bradycardia) 0 Flecaininde, digoxin Discontinuation of AAD
3 M/66 Sick sinus syndrome (Sinus bradycardia) 1 Metoprolol, amidarone Discontinuation of AAD
4 F/44 Sick sinus syndrome (Sinus pause) 1 Flecainide, atenolol Permanent PM
5 M/47 Sick sinus syndrome (Junctional bradycardia) 3 No Permanent PM
6 F/49 Sick sinus syndrome (Sinus bradycardia) 4 Flecainide, verapamil, Permanent PM
7 F/39 Sick sinus syndrome (Sinus pause) 6 Flecainide, atenolol Discontinuation of AAD
8 M/46 Tachybrady syndrome 26 Flecainide, propranolol Discontinuation of AAD
AAD, antiarrhythmic drug; ECG, electrocardiography; M, male; F, female; PM, pacemaker.
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was lower than those reported by previous studies.16,17 How-
ever, this study included the majority of AF >48 hours. A study, 
which included the majority of AF >48 hours, showed success-
ful rate similar to this study.14 
Earlier studies7,18,19 reported the risk of thromboembolism 
in the absence of adequate anticoagulation to be highest dur-
ing the first week following cardioversion (5.6%).8 In the pres-
ent study, stroke was observed during the first week in patients 
with low INR less than 2 at the time of admission due to a event. 
The use of anticoagulation in the setting of cardioversion has 
not adequately been evaluated in randomized prospective tri-
als, and the current recommendation of therapeutic anticoag-
ulation with warfarin for at least 3 weeks before and 4 weeks 
after cardioversion is based on small, nonrandomized obser-
vational and retrospective studies.8,11,20 Prospective therapeu-
tic warfarin data from the ACUTE and RE-LY trials have dem-
onstrated 30-day post cardioversion clinical thromboembolism 
rates of 0.5 and 0.6 percent, respectively.21,22 Others, however, 
have failed to show an agreement on predictors for these 
events.14,16,17 On the other hand, the present study demonstrat-
ed that patients with higher CHADS2, CHA2DS2-VASc, and 
HAS-BLED scores with a prior history of stroke/TIA and heart 
failure presented with a higher risk of thromboembolic or 
bleeding events after cardioversion, therefore, warrants care-
ful attention. 
As the risk of bleeding tends to be higher among Asians 
compared to Caucasians, some studies recommended main-
tenance of a lower target INR for prophylactic anticoagulation 
in Asian patients with AF.23-25 Nevertheless, the present study 
found that maintaining an INR of between 2 to 3 did not result 
in a higher risk of major bleeding, implying that it is perhaps 
safe to maintain an INR value as recommended for cardiover-
sion in AF.
Arrhythmic events
Previously, the prevalence of bradyarrhythmic events post-car-
dioversion has been reported to be between 0.8 and 1.5%.15,26-28 
In comparison, however, the prevalence of arrhythmic events 
related to hospitalization in the present study was relatively 
lower. Unlike previous studies, our present study restricted 
the outcome to only serious arrhythmic events requiring hos-
pitalization, which may, in part, explain the disparity in findings 
observed. In our study, 38% of patients hospitalized for brady-
arrhythmic events underwent permanent pacemaker inser-
tion. Consistently, Grönberg, et al.16 reported that permanent 
pacemaker was implanted in 44% of patients hospitalized for 
bradyarrhythma. The heart rate before cardioversion was sig-
nificantly lower in patients with bradyarrhythmic events. This 
result suggests that we should consider reducing the dosage of 
rate control drugs in patients with bradycardia before cardio-
version.
Study limitation
This study was cross-sectional in nature and limits any inter-
pretation of a causal inference. Inclusion of only Asian pa-
tients limits the generalizability and applicability of our find-
ings to other ethnic populations with AF. However, given that 
most of the previous investigations exploring AF cardiovascu-
lar events were performed in Caucasian populations, the find-
ings from this study in Asian population are important to re-
port. In addition, the study population was representative of 
patients referred for cardioversion at four tertiary care centers. 
The numbers of events that occurred may be insufficient in 
identifying a significant relationship between the presence of 
risk factors and greater risk of adverse cardiovascular events 
following electrical cardioversion in AF. On the other hand, 
however, this fact points out the fact that cardioversion accord-
ing to current guideline has a low cardiovascular events rate. 
Further studies aimed at validating the current study findings 
in other well-defined populations are needed.
Conclusion
In this study, the incidence of stroke/TIA, major bleedings, 
and arrhythmic events requiring a hospitalization following 
cardioversion was found to be low. These observations indi-
cate that the current electric cardioversion guidelines follow-
ing optimal anticoagulation for more than 4 weeks is safe and 
represents a low cardiovascular events rate, at least in an Asian 
population.
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